Jason Butler
Stock Analyst at Citizens
(4.65)
# 181
Out of 5,152 analysts
141
Total ratings
51.03%
Success rate
45.53%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Market Outperform | $88 → $96 | $62.19 | +54.37% | 18 | Feb 25, 2026 | |
| IRWD Ironwood Pharmaceuticals | Upgrades: Market Outperform | $8 | $3.62 | +120.99% | 2 | Jan 5, 2026 | |
| NSRX Nasus Pharma | Initiates: Market Outperform | $19 | $4.99 | +280.76% | 1 | Dec 18, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $114 → $131 | $112.70 | +16.24% | 5 | Dec 16, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $11 → $19 | $9.46 | +100.85% | 12 | Dec 1, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $92 | $67.36 | +36.58% | 14 | Nov 4, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $4.26 | +181.69% | 8 | Oct 9, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $29.65 | -5.56% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $22.40 | +65.18% | 15 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $15.17 | +157.09% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.37 | +78.04% | 11 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $115 → $100 | $29.79 | +235.68% | 1 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $28.96 | +31.22% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $8.79 | +104.78% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $2.77 | +44.40% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $728.11 | -3.72% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $3.13 | +187.54% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $6.30 | +201.59% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.94 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $8.57 | +489,981.68% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $13.74 | +744.25% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.70 | +91.49% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.85 | - | 1 | Dec 2, 2020 |
Cytokinetics
Feb 25, 2026
Maintains: Market Outperform
Price Target: $88 → $96
Current: $62.19
Upside: +54.37%
Ironwood Pharmaceuticals
Jan 5, 2026
Upgrades: Market Outperform
Price Target: $8
Current: $3.62
Upside: +120.99%
Nasus Pharma
Dec 18, 2025
Initiates: Market Outperform
Price Target: $19
Current: $4.99
Upside: +280.76%
ABIVAX Société Anonyme
Dec 16, 2025
Maintains: Market Outperform
Price Target: $114 → $131
Current: $112.70
Upside: +16.24%
Prothena Corporation
Dec 1, 2025
Maintains: Market Outperform
Price Target: $11 → $19
Current: $9.46
Upside: +100.85%
Halozyme Therapeutics
Nov 4, 2025
Maintains: Market Outperform
Price Target: $91 → $92
Current: $67.36
Upside: +36.58%
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $4.26
Upside: +181.69%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $29.65
Upside: -5.56%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $22.40
Upside: +65.18%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $15.17
Upside: +157.09%
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $3.37
Upside: +78.04%
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $29.79
Upside: +235.68%
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $28.96
Upside: +31.22%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $8.79
Upside: +104.78%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $2.77
Upside: +44.40%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $728.11
Upside: -3.72%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $3.13
Upside: +187.54%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $6.30
Upside: +201.59%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $5.94
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $8.57
Upside: +489,981.68%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $13.74
Upside: +744.25%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.70
Upside: +91.49%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.85
Upside: -